UC Davis Health Clinical Studies

A Study of the Experimental Medicine Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The main reason for you to take part in this study is to help in answering the following research questions: • How experimental baricitinib (LY3009104) compares with placebo in helping patients with atopic eczema. • The safety of baricitinib and any side effects you might have when you take it. “Experimental” means that the drug being tested has not been approved for routine clinical use or for the use described in this study by the FDA. The FDA is allowing the use of this drug for research.

Drug study, Phase 3
Any, age 18 years or older

Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis

Is photodynamic therapy more effective than topical treatments in the treatment of seborrheic dermatitis?

This study seeks to determine the effectiveness of a new treatment method called photodynamic therapy (PDT), a type of light therapy, in the treatment of seborrheic dermatitis. Seborrheic dermatitis is a common skin condition that causes scaly patches and red skin on the scalp, and oily areas of the body, such as the face, upper chest, and back. This study also seeks to determine how photodynamic therapy (PDT) alters the skin microbiome (bacteria normally found in the skin) in patients with seborrheic dermatitis before and after treatment.

Drug study
Any, age 18 and older